Brief: BioArctic AB Says EU Approves Leqembi (Lecanemab) For Treatment Of Early Alzheimer's Disease
15/04/2025 16:27
April 15 (Reuters) - Eisai Co Ltd 4523.T: BIOARCTIC AB - EU APPROVES LEQEMBI® (LECANEMAB) FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE Source text: ID:nWkr3hfLqX Further company coverage: 4523.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln